Alzheimer’s Eli Lilly
Eli Lilly’s solanezumab fails at Phase 2/3 in early-onset Alzheimer’s disease
February 11, 2020Manufacturing and Production Alzheimer's Eli Lilly, pharma, trial failure
In another blow to Alzheimer’s research, it has emerged that a study investigating Eli Lilly’s solanezumab in the treatment of …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
